刘倩颖, 孙立新 . 干扰性疟疾疫苗的研究进展[J]. 中国媒介生物学及控制杂志, 2015 , 26(1) : 104 -107 . DOI: 10.11853/j.issn.1003.4692.2015.01.030

[1] World Health Organization. World malaria report 2013[EB/OL].[2014-09-01]. http://www.who.int/malaria/publications/world_ malaria_report_2013/en/.
[2] The malERA consultative group on vaccines 2011. a research agenda for malaria eradication:vaccines[J]. PLoS Med,2011,8 (1):e1000398. doi:10.1371/journal.pmed.1000398.
[3] Mendis K,Sina BJ,Marchesini P,et al. The neglected burden of Plasmodium vivax malaria[J]. Am J Trop Med Hyg,2001, 64:97-106.
[4] Arakawa T,Tsuboi T,Sattabongkot J,et al. Tricomponent complex loaded with a mosquito-stage antigen of the malaria parasite induces potenttransmission-blocking immunity[J]. Clin Vaccine Immunol,2014,21(4):561-569.
[5] Sauerwein RW. Malaria transmission-blocking vaccines:the bonus of effective malaria control[J]. Microbes Infect,2007,12 (6):792-795.
[6] Carter R. Transmission blocking malaria vaccines[J]. Vaccine, 2001,19(17/19):2309-2314.
[7] Shimp RL Jr,Rowe C,Reiter K,et al. Development of a pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle[J]. Vaccine,2013,31(28): 2954-2962.
[8] Kaslow DC,Quakyi IA,Syin C,et al. A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains[J]. Nature,1988,333(6168):74-76.
[9] Nirbhay K. A vaccine to prevent transmission of human malaria: a long way to travel on duaty and often bumpy road[J]. Curr Sci, 2007,92(11):1535-1543.
[10] 陈勇,雷清,刘晓,等. 恶性疟原虫膜蛋白Pfs25在毕赤酵母中 的组成型表达[J]. 生物技术通讯,2011,22(6):785-788.
[11] Gregory JA,Li FW,Tomosada LM,et al. Algae-produced Pfs25 elicits antibodies that inhibit malaria transmission[J]. PLoS One,2012,7(5):e37179. doi: 10.1371/journal.pone.0037179.
[12] Duffy PE,Pimenta P,Kaslow DC. Pgs28 belongs to a family of epidermal growth factor-like antigens that are targets of malaria transmission-blocking antibodies[J]. J Exp Med,1993,177(2): 505-510.
[13] Gozar MMG,Muratova O, Keister DB,et al. Plasmodium falciparum:immunogenicity of alum-adsorbed clinical-grade TBV25-28,a yeast-secreted malaria transmission-blocking vaccine candidate[J]. Exp Parasitol,2001,97(2):61-69.
[14] Tomas AM,Margos G,Dimopoulos G,et al. P25 and P28 proteins of the malaria ookinete surface have multiple and partially redundant functions[J]. EMBOJ,2001,20(15): 3975-3983.
[15] Malkin EM,Durbin AP,Diemert DJ,et al. Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria[J]. Vaccine,2005,23(24) : 3131-3138.
[16] Miao J,Fan Q,Parker D,et al. Puf mediates translation repression of transmission-blocking vaccine candidates in malaria parasites[J]. PLoS Pathog,2013,9(4):e1003268. doi: 10.1371/journal.ppat.1003268.
[17] Feng H,Zheng L,Zhu XT, et al. Genetic diversity of transmission-blocking vaccine candidates Pvs25 and Pvs28 in Plasmodium vivax isolates from Yunnan province,China[J]. Parasit Vectors,2011,4:224.
[18] Hisaeda H,Stowers AW,Tsuboi T,et al. Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes[J]. Infect Immun, 2000,68(12):6618-6623.
[19] Barr TA,Carlring J,Heath AW. Co-stimulatory agonists as immunological adjuvants[J]. Vaccine,2006,24(17):3399-3407.
[20] Barr PJ,Green KM,Gibson HL,et al. Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals[J]. J Exp Med, 1991,174(5):1203-1208.
[21] Wu YM,Ellis RD,Shaffer D,et al. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51[J]. PLoS One,2008,3(7): e2636. doi: 10.1371/journal.pone.0002636.
[22] Qian F,Wu Y,Muratova O,et al. Con-jugating recombinant proteins to Pseudomonas aeruginosa ExoProtein A:a strategy for enhancing immunogenicity of malaria vaccine candidates[J]. Vaccine,2007,25(20):3923-3933.
[23] Kubler-Kielb J,Majadly F,Wu Y,et al. Long-lasting and transmission-blocking activity of antibodies to Plasmodium falciparum elicited in mice by protein conjugates of Pfs25[J]. Proc Natl Acad Sci USA,2007,104(1):293-298.
[24] Wu Y,Przysiecki C,Flanagan E,et al. Sustained high-titer antibody responses induced by conjugating a malarial vac-cine candidate to outer-membrane protein complex[J]. Proc Natl Acad Sci USA,2006,103(48):18243-18248.
[25] Miyata T,Harakuni T,Sugawa H,et al. Adenovirus-vectored Plasmodium vivax ookinete surface protein, Pvs25, as a potential transmission-blocking vaccine[J]. Vaccine,2011,29 (15):2720-2726.
[26] Alonso PL,Sacarlal J,Aponte JJ,et al. Efficacy of the RTS,S/ AS02A vaccine against Plasmodium falciparum infection and disease in young African children:randomised controlled trial[J]. Lancet,2004,364(9443):1411-1420.
[27] Alonso PL,Sacarlal J,Aponte JJ,et al. Duration of protection with RTS, S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children:single-blind extended follow-up of a randomised controlled trial[J]. Lancet,2005,366(9502):2012-2018.
[28] Dinglasan RR,Kalume DE,Kanzok SM,et al. Disruption of Plasmodium falciparum development by antibodies against a conserved mosquito midgut antigen[J]. Proc Natl Acad Sci USA, 2007,104(3):13461-13466.
[29] Foy BD,Magalhaes T,Injera WE,et al. Induction of mosquitocidal activity in mice immunized with Anopheles gambiae midgut cDNA[J]. Infect Immun,2003,71(4):2032-2040.
[30] Kimani D,Jagne YJ,Cox M,et al. Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations[J]. Mol Ther,2014,22(11):1992-2003.
[31] Stewart VA,McGrath SM,Dubois PM,et al. Priming with an adenovirus 35-circumsporozoite protein(CS)vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone[J]. Infect Immun,2007,75(5): 2283-2290.
[32] Tewari R,Spaccapelo R,Bistoni F,et al. Function of regionⅠ andⅡadhesive motifs of Plasmodium falciparum circumsporozoite protein in sporozoite motility and infectivity[J]. J Biol Chem, 2002,277(49):47613-47618.
[33] Pattnaik P,Shakri AR,Singh S,et al. Immunogenicity of a recombinant malaria vaccine based on receptor binding domain of Plasmodium falciparum EBA-175[J]. Vaccine,2007,25(5): 806-813.
[34] Pandey KC,Singh S,Pattnaik P,et al. Bacterially expressed and refolded receptor binding domain of Plasmodium falciparum EBA-175 elicits invasion inhibitory antibodies[J]. Mol Biochem Parasitol,2002,123(1):23-33.
[35] Grimberg BT,Udomsangpetch R,Xainli J,et al. Plasmodium vivax invasion of human erythrocytes inhibited by antibodies directed against the Duffy binding protein[J]. PLoS Med,2007, 4(12):e337. doi: 10.1371/journal.pmed.0040337.
[36] Gao XH,Yeo KP,Aw SS,et al. Antibodies targeting the PfRH1 binding domain inhibit invasion of Plasmodium falciparum merozoites[J]. PLoS Pathog,2008,4(7):e1000104. doi: 10.1371/journal.ppat.1000104.
[37] 陈华,杨恒林. 疟疾疫苗研究进展[J]. 中国病原生物学杂志, 2010,5(3):225-226,229.
[38] Tsuboi T,Tachibana M,Kaneko O,et al. Transmission-blocking vaccine of vivax malaria[J]. Parasitol Int,2003,52(1):1-11.
[39] Saul A,Fay MP. Human immunity and the design of multi-component,single target vaccines[J]. PLoS One,2007,2(9): e850. doi: 10.1371/journal.pone.0000850.